Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...

The company’s shares jumped 13.3% as the results of the trial, the first of several under way on the pill, orforglipron, ...

Lilly shares surged about 14 per cent after the results of the study emerged. US-listed shares of Ozempic maker Novo, down more than 50 per cent over the past year, dipped again on Thursday.

FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...